Also trades as: 9688.HK (HKSE) · $vol 19M
ZLAB NASDAQ
Zai Lab Limited
1W: -6.0%
1M: -8.2%
3M: +28.8%
YTD: +36.1%
1Y: -10.4%
3Y: -1.4%
5Y: -76.7%
$23.58
-0.76 (-3.12%)
Weekly Expected Move ±9.6%
$19
$22
$24
$26
$29
Credit Risk of going bust: lower than 51% of companies Debt: 8.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.43 (down 98%), Zai Lab Limited would be worth roughly what it owes.
Total debt $254.6M against a stock market value of $2.65B.
Distance to default 5.21 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $238.1M (short-term plus half of long-term), stock volatility 50.6%; Altman Z'' -5.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $254.6M against a stock market value of $2.65B.
Distance to default 5.21 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $238.1M (short-term plus half of long-term), stock volatility 50.6%; Altman Z'' -5.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships7
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2021-06-01
Earliest Filing
2025-10-16
Latest Filing
partner: 5
customer: 2
Counterparties (Filed by ZLAB)
7 relationshipsCompanies named in ZLAB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Zai Lab (Shanghai) Co., Ltd. | ZLAB | customer | Wholly-owned subsidiary that entered into the credit line contract with Industrial Bank | 2025-10-16 | View |
| Zai Lab (Shanghai) Co., Ltd. | ZLAB | customer | Wholly-owned subsidiary that entered into the Credit Agreement with China Merchants Bank | 2024-07-09 | View |
| Seagen Inc. | SGEN | partner | Collaboration and license agreement for TIVDAK® development and commercialization in mainland China, Hong Kong, Macau, a | 2022-09-27 | View |
| Blueprint Medicines Corporation | — | partner | License and collaboration agreement for development and commercialization of BLU-701 and BLU-945 in China, Macau, Hong K | 2021-11-09 | View |
| Karuna Therapeutics, Inc. | KRTX | partner | License agreement for collaborative development, manufacture, and commercialization of KarXT in China, Macau, Hong Kong, | 2021-11-09 | View |
| MacroGenics, Inc. | MGNI | partner | Collaboration and license agreement for bispecific antibody development and stock purchase agreement | 2021-06-16 | View |
| Mirati Therapeutics, Inc. | — | partner | Collaboration and license agreement for adagrasib development in China, Macau, Hong Kong, and Taiwan. | 2021-06-01 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ZLAB in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-17 | Shareholder Vote | View | |
| 2026-05-21 | Officer/Director Change | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-16 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-03 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2024-11-15 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2024-11-13 | Other Events; Financial Statements and Exhibits | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-07-09 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2024-06-11 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-02-08 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR